SillaJen’s next-generation oncology pipeline candidate BAL0891 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

BAL0891 - SillaJen

Aug 24, 2026